









Markets
/
Stocks
/
nasdaq-bdtx
/

Black Diamond Therapeutics Inc

BDTX

2.030USD

-0.100-4.69%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

66.25MMarket Cap

5.16P/E TTM



Black Diamond Therapeutics Inc

2.030

-0.100-4.69%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Black Diamond Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Black Diamond Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 21 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.71.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Black Diamond Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

21 / 391

Overall Ranking

103 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Black Diamond Therapeutics Inc Highlights

StrengthsRisks

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Growing

The company is in a growing phase, with the latest annual income totaling USD 70.00M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 5.16, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 45.27M shares, increasing 0.01% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 131.44K shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.714

Target Price

+356.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Black Diamond Therapeutics Inc is 9.22, ranking 8 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.22

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.27

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.82

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Black Diamond Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Black Diamond Therapeutics Inc is 7.06, ranking 176 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 5.16, which is 501.40% below the recent high of 31.04 and 186.50% above the recent low of -4.46.

Score

Industry at a Glance

Previous score

7.06

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 21/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Black Diamond Therapeutics Inc is 8.44, ranking 124 out of 391 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 13.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.714

Target Price

+378.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Black Diamond Therapeutics Inc

BDTX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Black Diamond Therapeutics Inc is 6.29, ranking 248 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.37 and the support level at 1.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.60

Change

-0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.004

Sell

RSI(14)

38.538

Neutral

STOCH(KDJ)(9,3,3)

20.225

Sell

ATR(14)

0.129

Low Volatility

CCI(14)

-196.500

Sell

Williams %R

96.429

Oversold

TRIX(12,20)

-0.440

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.128

Sell

MA10

2.149

Sell

MA20

2.191

Sell

MA50

2.336

Sell

MA100

2.771

Sell

MA200

2.929

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Black Diamond Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 104.04%, representing a quarter-over-quarter decrease of 2.54%. The largest institutional shareholder is The Vanguard, holding a total of 2.19M shares, representing 3.82% of shares outstanding, with 8.14% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Investment Management, Inc.

10.74M

+2.21%

Versant Ventures

6.21M

-3.45%

New Enterprise Associates (NEA)

4.45M

The Vanguard Group, Inc.

Star Investors

2.19M

+4.08%

Acadian Asset Management LLC

481.12K

Marshall Wace LLP

1.30M

+76.07%

Invus Public Equities Advisors, LLC

1.05M

Arrowstreet Capital, Limited Partnership

896.85K

+549.22%

Renaissance Technologies LLC

Star Investors

599.40K

+258.71%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Black Diamond Therapeutics Inc is 3.51, ranking 135 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 3.41. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Black Diamond Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.